PCN11 The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer
2016 ◽
Vol 2016
◽
Keyword(s):
Keyword(s):
Keyword(s):
1980 ◽
Vol 9
(2)
◽
pp. 383-404
◽